Literature DB >> 2323679

Algorithm for short-term prescription of phenprocoumon.

J Heaf1, B Guldager.   

Abstract

Data from the start of anticoagulation therapy using the coumarin derivative phenprocoumon were obtained retrospectively for 101 patients, and the correct long-term maintenance dose (MD) of the drug was determined. The average loading dose was 23.2 +/- 7.8 mg and the average MD 2.14 +/- 0.99 mg. The physician's prescription on discharge tended to underestimate the true MD by 0.29 +/- 0.64 mg. Significant positive correlations with MD were noted for loading dose and weight and negative correlations for age, serum creatinine, initial prothrombin ratio, and length of treatment pause (days) for patients receiving an excessive loading dose. Using stepwise variance analysis, an algorithm was obtained that predicted the MD: MD = -0.7 + loading dose/10 - treatment pause/7 - age/60 + initial prothrombin ratio. The accuracy (0.02 +/- 0.54 mg) was similar to that of the discharging physician. The algorithm required an average observation period of 5.4 days and the physician's estimate 12.4 days. It is suggested that the use of the algorithm would lead to shorter hospitalization without loss of treatment accuracy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323679     DOI: 10.1159/000216101

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  2 in total

1.  Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.

Authors:  Cordula Meyer zu Schwabedissen; Vera Mevissen; Fabian Schmitz; Seth Woodruff; Georg Langebartels; Thomas Rau; Klaus Zerres; Rainer Hoffmann; Jan R Ortlepp
Journal:  Eur J Clin Pharmacol       Date:  2006-07-18       Impact factor: 2.953

2.  VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients.

Authors:  Sea Mi Park; Jong-Keuk Lee; Sa Il Chun; Hae In Lee; Sun U Kwon; Dong-Wha Kang; Jong S Kim
Journal:  J Stroke       Date:  2013-05-31       Impact factor: 6.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.